Use of repaglinide on a pregnant woman during embryogenesis.
In the past few years, oral antihyperglycaemic agents have been considered as an alternative to insulin therapy in the treatment of gestational diabetes. There is still little information available on the safety of these drugs during pregnancy, but there have been several studies published regarding their use. Here we report on the case of a woman who took repaglinide up to the seventh week of pregnancy. Delivery occured with no complications and the newborn showed no malformations. Further studies are required to confirm the safety of repaglinide during pregnancy.
Mollar-Puchades
M A
MA
Martin-Cortes
A
A
Perez-Calvo
A
A
Diaz-Garcia
C
C
D000328:Adult; D002219:Carbamates / Q000494:pharmacology*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D047108:Embryonic Development / Q000187:drug effects*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D010880:Piperidines / Q000494:pharmacology*; D011247:Pregnancy; D011254:Pregnancy in Diabetics / Q000188:drug therapy*
D002219:Carbamates; D007004:Hypoglycemic Agents; D010880:Piperidines; C072379:repaglinide